|
|
Volumn 53, Issue 1, 2013, Pages 177-180
|
|
Clinical trials update - 2012: Year in review
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALD 403;
AMPA RECEPTOR AGONIST;
AMRIXL;
ANTIMIGRAINE AGENT;
BGG 492;
BMS 927711;
BUPIVACAINE;
CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST;
CYCLOBENZAPRINE;
DICLOFENAC;
DIHYDROERGOTAMINE MESILATE;
DR 105;
ETHINYLESTRADIOL PLUS LEVONORGESTREL;
LASMIDITAN;
LY 2300559;
LY 2951742;
METHYLPREDNISOLONE;
MK 1602;
MK 6096;
OREXIN 1 RECEPTOR;
OREXIN 2 RECEPTOR;
PF 04427429;
PLACEBO;
POTASSIUM BICARBONATE;
SUMATRIPTAN;
UNCLASSIFIED DRUG;
ZELRIX;
COMPARATIVE STUDY;
DEPRESSION;
DIABETIC NEUROPATHY;
DISEASE SEVERITY;
DRUG SAFETY;
DRUG TOLERABILITY;
EPISODIC MIGRAINE;
FOOD AND DRUG ADMINISTRATION;
HEADACHE;
HUMAN;
INSOMNIA;
MENSTRUAL MIGRAINE;
MIGRAINE;
MONOTHERAPY;
NERVE BLOCK;
OUTCOME ASSESSMENT;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
REVIEW;
TRANSFORMED MIGRAINE;
|
|
EID: 84872105680
PISSN: 00178748
EISSN: 15264610
Source Type: Journal
DOI: 10.1111/head.12001 Document Type: Review |
|
Times cited : (5)
|
|
References (0)
|
